Osvaren (Magnesium Carbonate Heavy, Calcium Acetate)

Magnesium carbonate (heavy), the active ingredient in Osvaren, is a phosphate binder presented as a solid oral formulation for gastrointestinal use. It binds dietary phosphate in patients with chronic kidney disease to help control serum phosphate levels. GNH USA supplies Osvaren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

GNH USA supplies Osvaren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Osvaren is a phosphate‑binding agent used in disorders of mineral metabolism that involve excess phosphate.

- Chronic kidney disease (CKD): helps lower serum phosphate concentrations. - End‑stage renal disease (ESRD) on dialysis: assists in maintaining target phosphate levels. - Hyperphosphatemia secondary to renal failure: reduces dietary phosphate absorption. - Post‑transplant hyperphosphatemia: supports phosphate control after kidney transplantation.

Adverse reactions to Osvaren are generally mild and related to its mineral content.

Common Side Effects: - Constipation: occasional difficulty with bowel movements. - Diarrhea: loose stools in some patients. - Nausea: mild stomach upset. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient taste alteration.

Serious or Rare Side Effects: - Hypercalcemia: elevated calcium levels requiring medical attention. - Hypermagnesemia: excess magnesium that may cause muscle weakness or cardiac effects. - Severe gastrointestinal obstruction: rare but serious blockage. - Allergic reaction: rash, itching, or swelling. - Metabolic alkalosis: disturbance in acid‑base balance.

When prescribing Osvaren, clinicians should consider patient‑specific factors and monitor relevant parameters.

- Renal function: assess baseline kidney function and adjust as needed. - Serum electrolytes: monitor calcium, magnesium and phosphate levels regularly. - Gastrointestinal health: evaluate for pre‑existing constipation or obstruction risk. - Concomitant phosphate binders: avoid overlapping therapies that may cause excess mineral load. - Pregnancy and lactation: use only if clearly needed, weighing potential benefits against risks. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Osvaren can interact with other medicines that affect mineral balance or gastrointestinal absorption.

Major Interactions (Avoid): - Calcium‑containing antacids: may increase calcium load and risk of hypercalcemia. - Oral iron supplements: can reduce phosphate‑binding efficacy of the product.

Moderate Interactions (Monitor Closely): - Loop diuretics: may alter calcium and magnesium excretion. - Vitamin D analogues: can increase calcium absorption, requiring electrolyte monitoring. - Proton pump inhibitors: may affect gastric pH and binding capacity. - Bicarbonate therapy: can modify magnesium balance. - Certain antibiotics (e.g., quinolones): chelation may reduce antibiotic absorption.